Loading...
XNASFOLD
Market cap2.70bUSD
Jan 10, Last price  
9.02USD
1D
-4.65%
1Q
-14.10%
Jan 2017
81.49%
IPO
-33.19%
Name

Amicus Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:FOLD chart
P/E
—
P/S
6.75
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.70%
Rev. gr., 5y
34.35%
Revenues
399m
+21.30%
0001,784,00014,967,00064,358,000922,00021,434,00018,411,000363,0001,224,00004,958,00036,930,00091,245,000182,237,000260,886,000305,514,000329,233,000399,356,000
Net income
-152m
L-35.92%
-8,807,102-19,972,289-46,344,910-41,167,000-39,355,000-6,567,000-54,936,000-44,412,000-48,785,000-59,633,000-68,926,000-132,118,000-200,042,000-284,002,000-348,995,000-356,388,000-276,852,000-250,460,000-236,568,000-151,584,000
CFO
-69m
L-58.52%
-18,124,349-33,888,79015,192,000-36,863,000-43,371,000-13,983,000-49,422,000-33,744,000-45,794,000-51,669,000-100,139,000-150,534,000-215,485,000-299,955,000-250,416,000-233,290,000-202,491,000-166,575,000-69,091,000
Earnings
Feb 26, 2025

Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
URL
https://www.amicusrx.com/
IPO date
May 31, 2007
Employees
484
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
399,356
21.30%
329,233
7.76%
Cost of revenue
189,707
315,276
Unusual Expense (Income)
NOPBT
209,649
13,957
NOPBT Margin
52.50%
4.24%
Operating Taxes
1,483
(5,471)
Tax Rate
0.71%
NOPAT
208,166
19,428
Net income
(151,584)
-35.92%
(236,568)
-5.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
92,935
(7,180)
BB yield
-2.22%
0.20%
Debt
Debt current
16,648
8,552
Long-term debt
493,936
503,698
Deferred revenue
4,656
Other long-term liabilities
13,282
8,939
Net debt
224,384
214,353
Cash flow
Cash from operating activities
(69,091)
(166,575)
CAPEX
(7,440)
(3,766)
Cash from investing activities
98,064
92,316
Cash from financing activities
61,677
(7,463)
FCF
152,245
22,198
Balance
Cash
286,200
293,595
Long term investments
4,302
Excess cash
266,232
281,435
Stockholders' equity
(2,675,915)
(2,541,780)
Invested Capital
3,302,754
3,124,604
ROIC
6.48%
0.63%
ROCE
33.45%
2.37%
EV
Common stock shares outstanding
295,165
289,057
Price
14.19
16.22%
12.21
5.71%
Market cap
4,188,384
18.67%
3,529,388
12.58%
EV
4,412,768
3,743,741
EBITDA
217,522
19,299
EV/EBITDA
20.29
193.99
Interest
50,149
37,119
Interest/NOPBT
23.92%
265.95%